Multiple Sclerosis

FDA Approves First Multiple Sclerosis Treatment for Pediatric Patients

FDA Approves First Multiple Sclerosis Treatment for Pediatric Patients

By

The FDA's decision was based on data from the Phase 3 PARADIGMS study (N=215) which evaluated the safety and efficacy of oral fingolimod vs interferon beta-1a injection in pediatric patients aged 10 to <18 years with relapsing MS.

Online Fatigue Management Feasible, Effective for Multiple Sclerosis

Online Fatigue Management Feasible, Effective for Multiple Sclerosis

By

Investigators designed a parallel-group, 2-arm, randomized controlled trial to evaluate ELEVIDA, an online fatigue management program based on cognitive behavioral therapy and other therapy-based strategies.

Dimethyl Fumarate May Be Safe, Effective for Pediatric Multiple Sclerosis

Dimethyl Fumarate May Be Safe, Effective for Pediatric Multiple Sclerosis

By

Previous studies have shown that delayed-release DMF is safe and effective in treating RRMS in adult patients. The goal of this study was to extend these analyses to evaluate DMF in pediatric patients with RRMS.

Alemtuzumab Associated With Acute Acalculous Cholecystitis, Ischemia in Relapsing-Remitting MS

Alemtuzumab Associated With Acute Acalculous Cholecystitis, Ischemia in Relapsing-Remitting MS

By

Cases of acalculous cholecystitis and a single case of acute coronary syndrome associated with the use of alemtuzumab are reported.

Efficacy of Disease-Modifying Drugs for Multiple Sclerosis May Decrease With Age

Efficacy of Disease-Modifying Drugs for Multiple Sclerosis May Decrease With Age

By

A regression model showed that efficacy of DMTs significantly decreased until age 53, after which disease progression is not affected by DMTs.

Ozanimod Superior to Interferon β-1a for Treatment of Relapsing Multiple Sclerosis

Ozanimod Superior to Interferon β-1a for Treatment of Relapsing Multiple Sclerosis

By

Researchers sought to compare the safety and efficacy of ozanimod vs interferon β-1a in individuals with relapsing multiple sclerosis.

Multiple Sclerosis Guidelines: AAN's Recommendations for Initiating, Switching, Stopping Disease-Modifying Therapy

Multiple Sclerosis Guidelines: AAN's Recommendations for Initiating, Switching, Stopping Disease-Modifying Therapy

By

The new guidelines focus on helping clinicians decide when to initiate, switch, or discontinue disease-modifying therapies for multiple sclerosis.

Are Vaccines Associated With Multiple Sclerosis Relapse?

Are Vaccines Associated With Multiple Sclerosis Relapse?

By

Researchers found there are no associations between vaccinations and multiple sclerosis relapse flares.

Cardiovascular Comorbidities Linked to Increased Brain Atrophy in Multiple Sclerosis

Cardiovascular Comorbidities Linked to Increased Brain Atrophy in Multiple Sclerosis

By

Researchers investigated the association between cardiovascular risk factors and the development of brain atrophy in individuals with multiple sclerosis.

Interaction of Alcohol, Smoking on Multiple Sclerosis Severity

Interaction of Alcohol, Smoking on Multiple Sclerosis Severity

By

A cross-sectional study aimed to assess the effect of smoking and alcohol consumption along with the interactions they have on the clinical course of multiple sclerosis.

Switching to Oral Fingolimod From Injectable Treatment Linked to Fewer MS Relapses

Switching to Oral Fingolimod From Injectable Treatment Linked to Fewer MS Relapses

By

As injectable disease-modifying therapies can be inconvenient for patients with MS, fingolimod offers an oral treatment option that is associated with significantly lower risk for relapse.

AAN: High Fish Intake Linked to Reduced Risk of Multiple Sclerosis

AAN: High Fish Intake Linked to Reduced Risk of Multiple Sclerosis

Compared with consuming fish less than once per month and no supplements, high fish intake was correlated with a significantly reduced risk of multiple sclerosis.

Fingolimod May Help Prevent Brain Volume Loss in Relapsing-Remitting Multiple Sclerosis

Fingolimod May Help Prevent Brain Volume Loss in Relapsing-Remitting Multiple Sclerosis

By

Participants who were treated with both doses of fingolimod experienced less overall progression of disability than those receiving placebo.

DMT Discontinuation in Older MS Patients: Clinical Outcomes Examined

DMT Discontinuation in Older MS Patients: Clinical Outcomes Examined

By

Of the total patients, 178 (29.7%) discontinued DMT during the study period with only 1 documented relapse occurring in the discontinuers.

Siponimod Reduces Disability Progression in Secondary Progressive Multiple Sclerosis

Siponimod Reduces Disability Progression in Secondary Progressive Multiple Sclerosis

By

Further research should focus on establishing whether siponimod exerts its effect on the pathogenic processes associated with disease progression or activity, or both.

Apheresis Associated With Clinical Improvement in Early Active Multiple Sclerosis

Apheresis Associated With Clinical Improvement in Early Active Multiple Sclerosis

By

The study was unable to verify whether the findings may be applicable for lesion locations other than those found with brain biopsies.

Combined Exercise Training Increases BDNF in Relapsing-Remitting MS

Combined Exercise Training Increases BDNF in Relapsing-Remitting MS

By

The effect of 8 weeks of combined exercise training on serum BDNF concentration was examined in patients with relapsing-remitting multiple sclerosis.

Smoking Associated With Increased Relapse Rate in Interferon Beta-Treated Relapsing-Remitting MS

Smoking Associated With Increased Relapse Rate in Interferon Beta-Treated Relapsing-Remitting MS

By

A cohort study evaluated the effects of smoking on disease activity in interferon beta-treated relapsing-remitting multiple sclerosis.

Female Gender, Natalizumab Exposure Associated With Increased Lymphopenia Risk in FNG-Treated MS

Female Gender, Natalizumab Exposure Associated With Increased Lymphopenia Risk in FNG-Treated MS

By

The impact of treatment with dimethyl fumarate and fingolimod on lymphocyte and leukocyte count was evaluated in patients with multiple sclerosis.

Reduced Risk for Multiple Sclerosis Linked to Greater Sun Exposure

Reduced Risk for Multiple Sclerosis Linked to Greater Sun Exposure

Risk of multiple sclerosis may be reduced with high sun exposure.

Multiple Sclerosis Drug Zinbryta Withdrawn From the Market

Multiple Sclerosis Drug Zinbryta Withdrawn From the Market

By

Daclizumab, an interleukin-2 (IL-2) receptor blocking antibody, was approved in May 2016 to treat adults with relapsing forms of MS.

New Glatiramer Acetate Dose Available for Relapsing Multiple Sclerosis

New Glatiramer Acetate Dose Available for Relapsing Multiple Sclerosis

By

Glatopa 40 mg has been launched for the treatment of relapsing multiple sclerosis.

Prenatal Exposure to Natalizumab in MS Linked to Miscarriage Risk

Prenatal Exposure to Natalizumab in MS Linked to Miscarriage Risk

Natalizumab exposure is associated with an increased risk of spontaneous abortion for pregnant women with multiple sclerosis.

Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder Disability Linked to Fatty Acid Intake

Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder Disability Linked to Fatty Acid Intake

By

Intakes of fats and types of fatty acids may affect disability severity in multiple sclerosis and neuromyelitis optica spectrum disorder.

Motivating Patients With Multiple Sclerosis May Improve Treatment Adherence, Outcomes

Motivating Patients With Multiple Sclerosis May Improve Treatment Adherence, Outcomes

By

Patients with multiple sclerosis who were motivated to remain adherent to treatment experienced overall better outcomes, including low relapse rates.

Screening for Comorbid Psychiatric Conditions in MS: Use of Validated Screening Tools

Screening for Comorbid Psychiatric Conditions in MS: Use of Validated Screening Tools

By

Barriers to using screening tools included lack of time and lack of insurance compensation.

Quality of Life in Relapsing vs Progressive Multiple Sclerosis

Quality of Life in Relapsing vs Progressive Multiple Sclerosis

By

Data obtained from the iConquerMS network highlight areas of quality of life that affect people with relapsing and progressive forms of MS and provide substantial basis for future research.

Examining the Relationship Between Vitamin D and Progressive Multiple Sclerosis

Examining the Relationship Between Vitamin D and Progressive Multiple Sclerosis

By

Vitamin D deficiency is a risk factor for multiple sclerosis.

Multiple Sclerosis Disability, Fatigue Reduced With Caffeine Intake

Multiple Sclerosis Disability, Fatigue Reduced With Caffeine Intake

By

The association suggests that caffeine consumption may play a protective role against multiple sclerosis-related disability.

Case Study: Improving Medication Adherence in MS Patients With Cognitive Deficits

Case Study: Improving Medication Adherence in MS Patients With Cognitive Deficits

By

Poor medication timing, incorrect doses, medication disorganization, and under- or over-medication are some of the medication adherence issues that can occur in patients with MS and cognitive symptoms.

Sign Up for Free e-newsletters

CME Focus